Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.7238 +0.0238 (+3.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Friday's pre-market session: top gainers and losers
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert
U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs. 
Via Benzinga
Topics Government
Exposures Political
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts
Via Benzinga
9 Analysts Have This To Say About Sangamo Therapeutics
Via Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday
Via Benzinga
RH, Five Below, Sangamo, Bank Of America, Tesla: Why These 5 Stocks Are On Investors' Radars Amid Trump Tariff Meltdown
The stock market experienced a significant downturn today, with the S&P 500 dropping nearly 5% to 5,396.52, marking its worst session since September 2022. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption
On Stocktwits, message volume about Lilly jumped by 23% over the past 24 hours, with retail sentiment turning more ‘bullish.’ 
Via Stocktwits
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Sangamo Therapeutics Stock Surges After The Bell: What's Going On?
Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co. 
Via Benzinga
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
From Sangamo Therapeutics, Inc.
Via Business Wire
8 Analysts Assess Sangamo Therapeutics: What You Need To Know
Via Benzinga
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading. 
Via Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB. 
Via Stocktwits
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For March 17, 2025
Via Benzinga
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi. 
Via Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Lower Midday As 2024 Comes To An End
Stocks are lower midday, as Wall Street heads for its second consecutive winning year. 
Via Talk Markets
Topics Stocks / Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Higher; House Prices Increase In October
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS